Aytu BioPharma Reports Record Revenue from ADHD Asset

Aytu Biopharma (Nasdaq: AYTU) has announced its financial and operational results for the fiscal 2024 second quarter. The company’s ADHD Portfolio (Adzenys XR-ODT® and Cotempla XR-ODT®) net revenue increased 49% to $16.6 million, compared to $11.1 million in the prior year period.

Josh Disbrow, Chairman and Chief Executive Officer of Aytu, commented, “Our ADHD Portfolio experienced a 49% year over year increase in net revenue during the second quarter to an Aytu record of $16.6 million driven by strong sales force execution and an enhanced commercial approach, along with continuing to leverage our innovative Aytu RxConnect platform, which we believe is a best-in-class patient support program.”

Highlights

Aytu’s consolidated net revenue was $22.9 million, compared to $26.3 million in the prior year period. The decrease is primarily due to the planned wind down of the Company’s Consumer Health Segment.

Net revenue from the company’s Rx Segment was $18.7 million compared to $18.0 million in the prior year period.

Consolidated operating income during Q2 2024 was $2.4 million compared to an operating loss of $6.9 million in the prior year period.

Net loss during Q2 2024 was $0.2 million, or $0.04 per share, compared to a net loss of $6.7 million, or $2.15 per share, in Q2 2023.

Consolidated adjusted EBITDA was $5.1 million in Q2 2024 compared to $0.7 million in the prior year period, a 599% increase.

The company had a cash balance of $19.5 million at December 31, 2023.

About Aytu BioPharma, Inc.

Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company’s prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com.

Share This Article

 

About the Author

Aytu BioPharma Reports Record Revenue from ADHD Asset

Catie Corcoran

Biotech Editor